MCID: KDN017
MIFTS: 61

Kidney Cancer

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Kidney Cancer

MalaCards integrated aliases for Kidney Cancer:

Name: Kidney Cancer 12 42 15
Renal Cancer 12 74 29 54 15
Renal Carcinoma 17 71
Kidney Neoplasm 17 71
Malignant Neoplasm of Kidney Except Pelvis 12
Malignant Neoplasm of Kidney 71
Malignant Tumour of Kidney 12
Renal Cell Carcinoma 71
Kidney Carcinoma 6
Kidney Neoplasms 43
Cancer, Kidney 39
Cancer, Renal 39

Classifications:



External Ids:

Disease Ontology 12 DOID:263
ICD9CM 34 189.0
MeSH 43 D007680
SNOMED-CT 67 93849006
ICD10 32 C64
UMLS 71 C0007134 C0022665 C0494158 more

Summaries for Kidney Cancer

MedlinePlus : 42 You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary : Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and clear cell renal cell carcinoma, and has symptoms including flank pain An important gene associated with Kidney Cancer is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are MicroRNAs in cancer and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Nicotine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and prostate.

Disease Ontology : 12 A urinary system cancer that is located in the kidney.

Wikipedia : 74 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Kidney Carcinoma in Situ

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 714)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 32.3 PVT1 MTOR MIR27A MIR210 MIR21 MIR17
2 clear cell renal cell carcinoma 31.4 PVT1 MTOR MIR210 MIR21 MET MEG3
3 neuroblastoma 30.7 MTOR MIR21 MIR17 MET MEG3 MALAT1
4 bladder cancer 30.5 RNY3 RNY1 PVT1 MIR21 MIR17 MIR141
5 malignant pleural mesothelioma 30.4 PVT1 MIR17 MET GAS5
6 diffuse large b-cell lymphoma 30.4 MTOR MIR210 MIR21 MIR17 MIR126 HOTAIR
7 microvascular complications of diabetes 3 30.3 PVT1 MIR21 MALAT1
8 polymyositis 30.3 MIR210 MIR21
9 laryngeal squamous cell carcinoma 30.2 MIR21 MALAT1 HOTAIR H19
10 lymphoma, non-hodgkin, familial 30.2 MTOR MIR27A MIR21 MIR17 MIR126
11 b-cell lymphoma 30.2 PVT1 MIR21 MIR17 MALAT1 HOTAIR GAS5
12 cholangiocarcinoma 30.2 MTOR MIR21 MIR141 MET MALAT1 H19
13 myeloma, multiple 30.2 PVT1 MTOR MIR21 MIR17 MIR126 MET
14 small cell cancer of the lung 30.2 MIR21 MALAT1 HOTAIR
15 melanoma 30.2 PVT1 MTOR MIR27A MIR210 MIR17 MIR141
16 pituitary adenoma 30.2 MEG3 MALAT1 HOTAIR H19
17 astrocytoma 30.1 PVT1 MIR21 HOTAIR H19 GAS5
18 osteoarthritis 30.1 MEG3 HOTAIR H19 GAS5
19 gallbladder cancer 30.1 MEG3 MALAT1 HOTAIR H19
20 gastric adenocarcinoma 30.1 MTOR MIR27A MET HOTAIR H19
21 osteogenic sarcoma 30.1 PVT1 MEG3 MALAT1 HOTAIR HIF1A-AS2 H19
22 connective tissue disease 30.1 MIR27A MIR210 MIR21 MIR17 MIR126
23 glioma susceptibility 1 30.0 MTOR MIR21 MEG3 MALAT1 HOTAIR HIF1A-AS2
24 arteries, anomalies of 30.0 MIR27A MIR210 MIR21 MIR17 MIR141 MIR126
25 liver cirrhosis 30.0 MEG3 MALAT1 HOTAIR GAS5
26 leukemia, acute lymphoblastic 30.0 MIR27A MIR210 MIR21 MIR17 MIR126
27 cell type cancer 30.0 MIR27A MIR210 MIR21 MIR17 MIR141 MIR126
28 bladder urothelial carcinoma 29.9 PVT1 MTOR MIR27A MEG3 MALAT1 HOTAIR
29 hepatocellular carcinoma 29.9 PVT1 MTOR MIR27A MIR21 MIR17 MIR141
30 leukemia, chronic lymphocytic 29.9 MIR27A MIR21 MIR17 MIR141 MIR126
31 oral squamous cell carcinoma 29.9 MIR27A MIR21 MIR17 MIR126 MEG3 MALAT1
32 leukemia, acute myeloid 29.9 MTOR MIR27A MIR210 MIR21 MIR17 MIR126
33 glioma 29.9 PVT1 MIR210 MIR21 MIR17 MET MEG3
34 lung cancer susceptibility 3 29.8 MTOR MIR21 MIR17 MIR126 MET MEG3
35 cervical cancer 29.7 RNY3 RNY1 PVT1 MTOR MIR27A MIR21
36 squamous cell carcinoma, head and neck 29.7 MIR27A MIR210 MIR21 MIR17 MIR141 MET
37 prostate disease 29.7 MIR27A MIR21 MIR17 MIR141 MIR126 MEG3
38 pancreatic cancer 29.5 PVT1 MTOR MIR27A MIR210 MIR21 MIR17
39 gastric cancer 29.5 PVT1 MTOR MIR27A MIR21 MIR17 MIR141
40 esophageal cancer 29.4 PVT1 MTOR MIR27A MIR21 MIR141 MIR126
41 ovarian cancer 29.3 PVT1 MTOR MIR27A MIR210 MIR21 MIR17
42 prostate cancer 29.2 RNY3 RNY1 PVT1 MTOR MIR27A MIR210
43 breast cancer 29.1 PVT1 MTOR MIR27A MIR210 MIR21 MIR17
44 lung cancer 29.0 RNY3 RNY1 PVT1 MTOR MIR27A MIR210
45 colorectal cancer 29.0 RNY3 RNY1 PVT1 MTOR MIR27A MIR21
46 childhood multilocular cystic kidney neoplasm 12.2
47 kidney carcinoma in situ 12.2
48 inherited renal cancer-predisposing syndrome 12.1
49 hereditary leiomyomatosis and renal cell cancer 11.6
50 collecting duct carcinoma 11.5

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer

Symptoms & Phenotypes for Kidney Cancer

UMLS symptoms related to Kidney Cancer:


flank pain

Drugs & Therapeutics for Kidney Cancer

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 528)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
5
Caffeine Approved Phase 4 58-08-2 2519
6
Ibuprofen Approved Phase 4 15687-27-1 3672
7
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
8
Papaverine Approved, Investigational Phase 4 58-74-2, 61-25-6 4680
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
14
tannic acid Approved Phase 4 1401-55-4
15
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
16
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
17
Remifentanil Approved Phase 4 132875-61-7 60815
18
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
19
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
20
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
21 Antirheumatic Agents Phase 4
22 Neurotransmitter Agents Phase 4
23 Narcotics Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Anti-Anxiety Agents Phase 4
26 Tranquilizing Agents Phase 4
27 Psychotropic Drugs Phase 4
28 Adrenergic Agents Phase 4
29 Anti-Inflammatory Agents, Non-Steroidal Phase 4
30 Cyclooxygenase Inhibitors Phase 4
31 Adrenergic Agonists Phase 4
32 Central Nervous System Stimulants Phase 4
33 Nicotinic Agonists Phase 4
34 Adjuvants, Anesthesia Phase 4
35 Dopamine Uptake Inhibitors Phase 4
36 Antidepressive Agents Phase 4
37 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
38 GABA Agents Phase 4
39 GABA Modulators Phase 4
40 Adrenergic alpha-2 Receptor Agonists Phase 4
41 Liver Extracts Phase 4
42 Anti-Arrhythmia Agents Phase 4
43 Antipyretics Phase 4
44 Phosphodiesterase Inhibitors Phase 4
45 Analgesics, Opioid Phase 4
46 Sodium Channel Blockers Phase 4
47 Diuretics, Potassium Sparing Phase 4
48 Dexamethasone 21-phosphate Phase 4
49 Analgesics, Non-Narcotic Phase 4
50 Analgesics Phase 4

Interventional clinical trials:

(show top 50) (show all 1810)
# Name Status NCT ID Phase Drugs
1 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
2 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Unknown status NCT01413607 Phase 4
3 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
4 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
5 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
6 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
7 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
8 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
9 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
10 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
11 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
12 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
13 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
14 A Single-Center Double Arm Single-Blinded Randomized Screening Clinical Trial to Evaluate the Use of Human Dehydrated Amnion/Chorion Membrane to Facilitate the Recovery of Renal Function Following Robotic Partial Nephrectomy Completed NCT03323021 Phase 4
15 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
16 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4 Sunitinib;Erlotinib;Midazolam;Caffeine
17 Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Caesarean Section. A Double Blind, Randomized, Placebo Controlled Trial. Completed NCT03068260 Phase 4 Ropivacaine;Saline;Acetaminophen;Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet;Morphine
18 ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial Recruiting NCT02399124 Phase 4
19 Effect of Papaverine on Intraoperative Renal Artery Blood Flow Volume in Patients Undergoing Robot-assisted Partial Nephrectomy : a Randomized, Double-blind, Placebo-controlled Study Recruiting NCT04162834 Phase 4 Papaverine;Normal saline
20 A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy Recruiting NCT03824808 Phase 4 Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;0.9% Sodium Chloride Injection
21 Quadratus Lumborum Block (QLB) With and Without Dexamethasone: the Effect on Postoperative Pain and Recovery After Laparoscopic Nephrectomy Recruiting NCT03339284 Phase 4 Dexamethasone sodium phosphate;Ropivacaine Hydrocloride;Sodium Chloride 9mg/mL
22 Improving Postoperative Pain Management With the Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy and Robot-assisted Partiel Nephrectomy: A Double Blind, Randomized, Placebo Controlled Trial Recruiting NCT03571490 Phase 4 Ropivacaine;Saline
23 Randomized, Double-Blind Clinical Study Evaluating Efficacy of Intravenous Versus Enteric Acetaminophen in Donor Nephrectomy and Robot-Assisted, Laparoscopic Nephrectomy. Recruiting NCT03365622 Phase 4 acetaminophen;Acetaminophen;Placebos;Placebo Oral Tablet
24 Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT02733809 Phase 4 Sorafenib
25 Safety Study of Nivolumab for Selected Advanced Malignancies in India Active, not recruiting NCT03444766 Phase 4 Nivolumab
26 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Active, not recruiting NCT02596035 Phase 4 Nivolumab
27 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Active, not recruiting NCT02570789 Phase 4 patients with sunitinib or pazopanib
28 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Active, not recruiting NCT02555748 Phase 4 Pazopanib;Sunitinib
29 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
30 Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
31 Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging Not yet recruiting NCT04021238 Phase 4 Perflutren lipid microsphere;Sulfur hexafluoride lipid microspheres
32 Correlation of Contrast Enhanced Ultrasound of Renal Masses With Pathologic Grade: A Prospective Comparison of Quantitative and Qualitative Findings Not yet recruiting NCT03821376 Phase 4 Contrast enhanced ultrasound with Lumason
33 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
34 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
35 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
36 Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
37 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
38 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
39 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
40 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
41 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
42 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
43 Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail Unknown status NCT02928692 Phase 3 Minocycline;Placebo
44 A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer Unknown status NCT02044354 Phase 3 Taxotere;Jevtana
45 A Comparative Study of PET/CT Versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients With Renal Masses Using Iodine-124 Labeled Chimeric G250 (124I-cG250) Completed NCT00606632 Phase 3 124-Iodine-cG250 (124I-cG250)
46 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2
47 A Randomized Phase III Trial Of Interferon Alfa-2B Or Interferon Alfa-2B Plus Bevacizumab In Patients With Advanced Renal Carcinoma Completed NCT00072046 Phase 3
48 A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma Completed NCT00033904 Phase 3 autologous human tumor-derived HSPPC-96
49 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
50 A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00053820 Phase 3 fluorouracil

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Lomustine
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: kidney neoplasms

Genetic Tests for Kidney Cancer

Genetic tests related to Kidney Cancer:

# Genetic test Affiliating Genes
1 Renal Cancer 29

Anatomical Context for Kidney Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

19
Kidney

MalaCards organs/tissues related to Kidney Cancer:

40
Kidney, Lung, Prostate, Bone, Breast, Brain, T Cells

Publications for Kidney Cancer

Articles related to Kidney Cancer:

(show top 50) (show all 9256)
# Title Authors PMID Year
1
Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. 61 46
19646430 2010
2
Investigational MET inhibitors to treat Renal cell carcinoma. 42
31554440 2019
3
Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma. 42
31468240 2019
4
Percutaneous image-guided renal ablations: Current evidences for long-term oncologic efficacy. 42
31445699 2019
5
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. 54 61
20091131 2010
6
Multi-modal treatment for metastatic renal cancer: the role of surgery. 54 61
20364382 2010
7
Screening for kidney cancer: is there a role for aquaporin-1 and adipophilin? 54 61
20435833 2010
8
The genetic basis of kidney cancer: a metabolic disease. 54 61
20448661 2010
9
Urinary biomarkers for the early diagnosis of kidney cancer. 54 61
20375178 2010
10
Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. 54 61
20425594 2010
11
Influence of osteopontin short hairpin RNA on the proliferation and invasion of human renal cancer cells. 54 61
20155457 2010
12
Compounds in clinical Phase III and beyond. 54 61
20033382 2010
13
Molecular diagnosis and therapy of kidney cancer. 54 61
20059341 2010
14
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 54 61
20054297 2010
15
Molecular basis for the treatment of renal cell carcinoma. 54 61
20080466 2010
16
Management of vascular endothelial growth factor and multikinase inhibitor side effects. 54 61
19948455 2009
17
The sterol-sensing endoplasmic reticulum (ER) membrane protein TRC8 hampers ER to Golgi transport of sterol regulatory element-binding protein-2 (SREBP-2)/SREBP cleavage-activated protein and reduces SREBP-2 cleavage. 54 61
19706601 2009
18
In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. 54 61
19801515 2009
19
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. 54 61
19639177 2009
20
VHL loss causes spindle misorientation and chromosome instability. 54 61
19620968 2009
21
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. 54 61
19470762 2009
22
Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? 54 61
19663736 2009
23
TGF-alpha as a candidate tumor antigen for renal cell carcinomas. 54 61
19052740 2009
24
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. 54 61
19451442 2009
25
P-glycoprotein activity in renal clear cell carcinoma. 54 61
18440836 2009
26
[Case of drug-induced colitis like ulcerative colitis during IL-2 therapy for multiple bone metastasis after operation of kidney cancer]. 54 61
19663247 2009
27
Targeting the Met signaling pathway in renal cancer. 54 61
19496715 2009
28
The role of antiangiogenesis therapy: bevacizumab and beyond. 54 61
19531449 2009
29
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. 54 61
19675744 2009
30
Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. 54 61
19402056 2009
31
Hereditary kidney cancer: unique opportunity for disease-based therapy. 54 61
19402075 2009
32
Proepithelin is an autocrine growth factor for bladder cancer. 54 61
19237611 2009
33
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. 54 61
19318488 2009
34
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. 54 61
19409039 2009
35
[Hereditary renal cancer]. 54 61
19418834 2009
36
mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. 54 61
19236264 2009
37
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. 54 61
19238017 2009
38
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. 54 61
19165638 2009
39
[IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma]. 54 61
19452104 2009
40
Implication of bevacizumab in fatal arterial thromboembolic incidents. 54 61
19365880 2009
41
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. 54 61
19891126 2008
42
Kidney cancer: now available in a new flavor. 54 61
19061830 2008
43
Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. 46
18925646 2008
44
Absence of fumarate hydratase mutation in a family with cutaneous leiomyosarcoma and renal cancer. 54 61
18986479 2008
45
Sunitinib (SUTENT) for the treatment of metastatic renal cell carcinoma. 54 61
18928373 2008
46
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1. 54 61
18243508 2008
47
Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. 54 61
18806787 2008
48
Conclusion and future directions. 54 61
18836339 2008
49
Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer. 54 61
18794104 2008
50
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. 54 61
18676741 2008

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MET NM_001127500.3(MET):c.3335A>G (p.His1112Arg)SNV Pathogenic 13887 rs121913243 7:116417464-116417464 7:116777410-116777410
2 MET NM_001127500.3(MET):c.3743A>G (p.Tyr1248Cys)SNV Pathogenic/Likely pathogenic 13885 rs121913246 7:116423414-116423414 7:116783360-116783360
3 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr)SNV Pathogenic/Likely pathogenic 376129 rs587777894 1:11184573-11184573 1:11124516-11124516
4 MTOR NM_004958.4(MTOR):c.4379T>C (p.Leu1460Pro)SNV Pathogenic/Likely pathogenic 376130 rs1057519779 1:11217299-11217299 1:11157242-11157242
5 MET NM_001127500.3(MET):c.3334C>T (p.His1112Tyr)SNV Likely pathogenic 376068 rs121913244 7:116417463-116417463 7:116777409-116777409
6 MET NM_001127500.3(MET):c.3803T>C (p.Met1268Thr)SNV Likely pathogenic 376126 rs121913245 7:116423474-116423474 7:116783420-116783420
7 MTOR NM_004958.4(MTOR):c.7514G>C (p.Arg2505Pro)SNV Likely pathogenic 376127 rs1057519777 1:11169361-11169361 1:11109304-11109304
8 MTOR NM_004958.4(MTOR):c.6667C>A (p.Gln2223Lys)SNV Likely pathogenic 376128 rs1057519778 1:11182179-11182179 1:11122122-11122122
9 MET NM_001127500.3(MET):c.3742T>C (p.Tyr1248His)SNV Uncertain significance 194929 rs121913247 7:116423413-116423413 7:116783359-116783359

Cosmic variations for Kidney Cancer:

9 (show top 50) (show all 852)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94289415 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 36
2 COSM88289113 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-2A>T p.? 3:10146512-10146512 36
3 COSM88297043 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 36
4 COSM88292918 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.500G>A p.R167Q 3:10149823-10149823 36
5 COSM88288959 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.482G>A p.R161Q 3:10149805-10149805 36
6 COSM88292107 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.256C>T p.P86S 3:10142103-10142103 36
7 COSM88293667 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.548C>A p.S183* 3:10149871-10149871 36
8 COSM88289297 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 3:10142113-10142113 36
9 COSM88290436 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 3:10146526-10146526 36
10 COSM88292022 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 3:10142092-10142092 36
11 COSM88289282 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.217C>T p.Q73* 3:10142064-10142064 36
12 COSM88291948 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.234T>G p.N78K 3:10142081-10142081 36
13 COSM88304413 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.292T>G p.Y98D 3:10142139-10142139 36
14 COSM85360217 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176= 3:124737785-124737785 36
15 COSM87037342 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2356-1G>C p.? 16:2074199-2074199 36
16 COSM87037337 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1636G>T p.E546* 16:2065555-2065555 36
17 COSM87037202 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.976-1G>A p.? 16:2060669-2060669 36
18 COSM87030528 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3412C>T p.R1138* 16:2080179-2080179 36
19 COSM87037219 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1717-1G>C p.? 16:2070455-2070455 36
20 COSM87037265 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.774+1G>A p.? 16:2056770-2056770 36
21 COSM87049432 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.541G>A p.V181M 16:2055461-2055461 36
22 COSM87037238 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.390C>G p.Y130* 16:2054349-2054349 36
23 COSM87037320 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.731G>T p.C244F 16:2056726-2056726 36
24 COSM87036869 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1119+1G>T p.? 16:2060814-2060814 36
25 COSM87037346 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.975+1G>T p.? 16:2058874-2058874 36
26 COSM87037324 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1189C>T p.Q397* 16:2061940-2061940 36
27 COSM87036879 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1600-1G>T p.? 16:2065518-2065518 36
28 COSM85719503 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2287C>T p.Q763* 9:132902709-132902709 36
29 COSM85723777 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1276G>T p.D426Y 9:132907358-132907358 36
30 COSM85727708 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1001C>A p.S334* 9:132911481-132911481 36
31 COSM85723822 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.508+1G>T p.? 9:132923347-132923347 36
32 COSM85723770 TSC1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1835T>A p.L612* 9:132905743-132905743 36
33 COSM89062698 TRIO kidney,NS,carcinoma,renal cell c.9008A>G p.N3003S 5:14508136-14508136 36
34 COSM87921270 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.673-1G>T p.? 17:7674291-7674291 36
35 COSM88453050 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.97-2A>C p.? 17:7676274-7676274 36
36 COSM87908091 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.404G>T p.C135F 17:7675208-7675208 36
37 COSM87935614 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.738G>A p.M246I 17:7674225-7674225 36
38 COSM87898709 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.742C>T p.R248W 17:7674221-7674221 36
39 COSM87912624 TP53 kidney,NS,carcinoma,renal cell carcinoma unclassified c.374C>G p.T125R 17:7675995-7675995 36
40 COSM84063376 TBX3 kidney,NS,carcinoma,renal cell carcinoma unclassified c.510G>T p.W170C 12:114681026-114681026 36
41 COSM86748896 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2096+1G>A p.? 23:124065947-124065947 36
42 COSM86759462 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2860C>T p.R954C 23:124081464-124081464 36
43 COSM86766292 STAG2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1348A>T p.R450* 23:124057909-124057909 36
44 COSM100989027 SPOP kidney,NS,carcinoma,renal cell carcinoma unclassified c.265T>G p.L89V 17:49619321-49619321 36
45 COSM90109955 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1014-2A>T p.? 22:23833570-23833570 36
46 COSM90104263 SMARCB1 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1157G>A p.R386H 22:23834152-23834152 36
47 COSM89651052 SMARCA4 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3575G>A p.R1192H 19:11033318-11033318 36
48 COSM103036406 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1409C>A p.S470* 3:47123227-47123227 36
49 COSM103027937 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2372C>A p.S791* 3:47122264-47122264 36
50 COSM103046610 SETD2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.7431+1G>A p.? 3:47019759-47019759 36

Copy number variations for Kidney Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 166351 3 10158318 10168746 Mutations VHL Renal cancer

Expression for Kidney Cancer

Search GEO for disease gene expression data for Kidney Cancer.

Pathways for Kidney Cancer

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 MTOR MIR27A MIR210 MIR21 MIR17 MIR141
2 10.03 MEG3 HOTAIR

GO Terms for Kidney Cancer

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.73 MTOR MIR21 MIR126 MET
2 positive regulation of osteoblast differentiation GO:0045669 9.63 MIR210 MIR21 HIF1A-AS2
3 cellular response to hypoxia GO:0071456 9.62 MTOR MIR17 MIR126 MALAT1
4 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.58 MIR27A MIR21 MIR17
5 miRNA mediated inhibition of translation GO:0035278 9.56 MIR27A MIR210 MIR21 MIR17
6 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.52 MIR21 MIR17
7 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.51 MIR27A MIR17
8 regulation of protein kinase B signaling GO:0051896 9.49 MTOR MIR21
9 positive regulation of metalloendopeptidase activity GO:1904685 9.48 MIR21 MIR17
10 gene silencing by miRNA GO:0035195 9.43 MIR27A MIR210 MIR21 MIR17 MIR141 MIR126
11 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.37 MIR21 MET
12 positive regulation of vascular endothelial cell proliferation GO:1905564 9.33 MIR27A MIR21 MIR126
13 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 8.8 MIR210 MIR21 MIR17

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR27A MIR210 MIR21 MIR17 MIR141 MIR126

Sources for Kidney Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....